Summary
The pharmacokinetics of a new tablet formulation of carbamazepine, an antiepileptic agent, have been investigated in 9 normal healthy subjects. The drug was given as a single oral dose of 400 mg. Ten blood samples were collected after administration. Plasma carbamazepine concentrations were determined by a sensitive method (HPLC). Areas under the plasma level-time curves for each subject were evaluated by means of the trapezoidal rule. The peak plasma concentration of 3.96–8.25 mg/l was reached 4–24 h after drug administration. The terminal phase half-life was 22.19–39.61 h and a systemic clearance was 1.05–2.06 l/h. The new tablet formulation of carbamazepine seems to be bioequivalent when compared to the one used so far. For the prediction of systemic availability and estimation of the first-pass metabolism from plasma level data, a hepatic blood flow rate limited model were used. The systemic availability was 97.8–98.9% and the elimination of the drug on its first-pass through the liver was 1.13–2.20%.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
So E.L. (1993): Update on epilepsy. Med. Clin. North Am., 77, 203–214.
Treiman D.M. (1993): Current treatment strategies in selected situations in epilepsy. Epilepsia, 34, Suppl 5, S17-S23.
Janicak P.G. ({dy1993}): The relevance of clinical pharmacokinetics and therapeutic drug monitoring: anticonvulsant mood stabilizers and antipsychotics. J. Clin. Psychiatry, 54 Suppl. 35–41, discussion 55–56.
McKee P.J., Larkin J.G., Brodie A.F., Percy-Robb I.W., Brodie M.J. (1993): Five years of anticonvulsant monitoring on site at the epilepsy clinic. Ther. Drug. Monit., 15, 83–90.
Mauskop A. (1993): Trigeminal neuralgia (tic douloureux). J. Pain. Symptom. Manage., 8, 148–154.
Miller R., Ludden T.M. (1993): Bioavailability of controlled release carbamazepine estimated by mixed effect modelling. Eur. J. Clin. Pharmacol., 44, 231–235.
Bialer M. (1993): Comparative pharmacokinetics of the newer antiepileptic drugs. Clin. Pharmacokinet., 24, 441–452.
Riad L.E., Chan K.K., Sawchuk R.J. (1993): Transient steady-state analysis: application in the determination of the relative formation and elimination clearances of two major carbamazepine metabolites in humans. Pharm. Res., 10(7): 1090–2.
Bonneton J., Iliadis A., Genton P., Dravet C., Viallat D., Mesdjian E. (1993): Steady-state pharmacokinetics of conventional versus controlled-release carbamazepine in patients with epilepsy. Epilepsy Res., 14, 257–263.
Chapron D.J., LaPierre B.A., Abou-Elkair M. (1993): Unmasking the significant enzyme-inducing effects of phenytoin on serum carbamazepine concentrations during phenytoin withdrawal. Ann. Pharmacother., 27, 708–711.
Amabeoku G.J., Chikuni O., Akino C., Mutetwa S. (1993): Pharmacokinetic interaction of single doses of quinine and carbamazepine, phenobarbitone and phenytoin in healthy volunteers. East. Afr. Med. J., 70, 90–93.
Soldin J.S., Gilbert J.H. (1976): Rapid micromethod for measuring anticonvulsant drugs in serum by high-performance liquid chromatography. Clin. Chem., 22, 856–859.
Gibaldi M., Boyes R.N., Feldman S. (1971): Influence of first-pass effect on availability of drugs on oral administration. J. Pharm. Sci., 60, 1338–1340.
Perrier D., Gibaldi M., Boyes R.N. (1973): Prediction of systemic availability from plasma-level data after oral drug administration. J. Pharm. Pharmacol., 25, 256–257.
Gibaldi M., Perrier D. (1975): Pharmacokinetics. New York, Marcel Dekker.
Vaughan D.P. (1975): Estimation of biological availability after drug administration when the drug is eliminated by urinary excretion and metabolism. J. Pharm. Pharmacol., 27, 458–461.
McLean A.J., McNamara P.J., duSouich P., Gibaldi M., Lalka D. (1978): Food, splanchnic blood flow, and bioavailability of drugs subject to first-pass metabolism. Clin. Pharmacol. Ther., 24, 5–10.
Popović J. (1985): Estimation of the first-pass metabolism of a drug during multiple oral dosage. Periodicum Biologorum, 87, 290–292.
Popović J. (1985): Influence of first-pass effect on availability of drugs with simultaneous biotransformation in the liver and first-order elimination through kidneys. Iugoslav. Physiol. Pharmacol. Acta, 21 (Suppl. 3), 289–290.
Popović J. (1986): Dosage regimen calculations for drugs with first-order absorption, non-linear first-pass metabolism and parallel non-linear and first-order elimination. Periodicum Biologorum, 88, 183–184.
Popović J. (1987): Relationship between the steady-state serum level and the dose of drugs with first-pass and parallel Michaelis-Menten and first-order elimination. Acta Pharm. Jugost., 37, 313–317.
Balant L.P., Benet L.Z., Blume H., Bozler G., Breimer D.D., Eichelbaum M. (1991): Is there a need for more precise definitions of bioavailability? Eur. J. Clin. Pharmacol., 40, 123–126.
Salmonson T., Rane A. (1990): Clinical pharmacokinetics in the drug regulatory process. Clin. Pharmacokinet., 18, 177–183.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Popović, J., Mikov, M. & Jakovljevic, V. Pharmacokinetics of carbamazepine derived from a new tablet formulation. European Journal of Drug Metabolism and Pharmacokinetics 20, 297–300 (1995). https://doi.org/10.1007/BF03190248
Received:
Issue Date:
DOI: https://doi.org/10.1007/BF03190248